Connect with us


What are the differences between Canada’s approved COVID-19 vaccines? Here’s what we know – Global News



Now that the Oxford-AstraZeneca vaccine has been approved for use in Canada, three different jabs are on the menu for Canadians hoping to protect themselves against the coronavirus.

However, while all the vaccines have the same goal — to inoculate the recipient against COVID-19 — the vaccines are by no means identical.

Read more:
Canada approves AstraZeneca’s COVID-19 vaccine

And while Canada’s contracts secure enough doses from the three manufacturers to vaccinate everyone in the country by September, not everyone will be getting the same kind of jab.

Global News has broken down the key details of the three vaccines to help you understand which dose is going into your arm.

What kinds of COVID-19 vaccines are available?

  • Pfizer: mRNA
  • Moderna: mRNA
  • AstraZeneca: adenovirus-based

All of these vaccines use fairly new vaccine technologies, but they don’t all use the same kind.

Story continues below advertisement

Pfizer and Moderna’s vaccines use mRNA technology, which delivers genetic instructions for our cells to make viral proteins themselves. The body then begins to train itself to fight these proteins, building its immunity to the same protein found in COVID-19.

Click to play video 'Coronavirus: The science behind the new Covid-19 mRNA vaccines'

Coronavirus: The science behind the new Covid-19 mRNA vaccines

Coronavirus: The science behind the new Covid-19 mRNA vaccines – Jan 23, 2021

The Oxford-AstraZeneca vaccine works differently. It was built using a kind of virus called an adenovirus, which causes colds in chimpanzees. These adenovirus-based vaccines represent a newly approved method of vaccination that has been studied for decades. The adenovirus is altered to carry a gene for the coronavirus protein, which can then train a person’s immune system to recognize the actual coronavirus if it ever enters the body.

How effective are the COVID-19 vaccines?

  • Pfizer: 95 per cent
  • Moderna: 94.1 per cent
  • AstraZeneca: 62 per cent

Each of the vaccines has been found to be effective in combatting the coronavirus. However, they don’t all offer the same amount of protection.

Story continues below advertisement

Pfizer and Moderna have a photo-finish for first place in terms of effectiveness. Clinical trials found Pfizer’s vaccine was 95 per cent effective, while Moderna’s vaccine nipped at Pfizer’s heels with an effectiveness of 94.1 per cent.

The distant bronze goes to the Oxford-AstraZeneca vaccine, which was found to be 62 per cent effective in a two-dose clinical trial.

Click to play video 'Tracking the global race to vaccinate against COVID-19'

Tracking the global race to vaccinate against COVID-19

Tracking the global race to vaccinate against COVID-19 – Jan 24, 2021

However, researchers accidentally gave a sub-group of participants a half-dose on their first jab of the Oxford-AstraZeneca jab, followed up by a full second dose. This group saw a leap in the vaccine’s ability to shield them from the virus, with the outcome proving to be 90 per cent effective.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Because this was just a sub-group within the clinical trial, the vaccine was only approved for use in its full, two-dose iteration — which is over 30 per cent less effective than Pfizer and Moderna’s vaccines.

Story continues below advertisement

Still, at the end of the day, Canadians should feel confident that any one of the three approved vaccines will cut off COVID-19’s claws and protect them from the worst outcomes of the virus.

“If there is a vaccine and it’s been authorized by Health Canada, it means that it’s met standards,” said Dr. Supriya Sharma, chief medical advisor with the regulatory branch of Health Canada, said on Friday.

She explained that in clinical trials, all the vaccines were found to quash the worst outcomes in coronavirus patients.

“The number of cases of people that died from COVID-19 that got vaccine was zero. The number of people that were hospitalized because their COVID-19 disease was so severe was zero. The number of people that died because of an adverse event or an effect of the vaccine was zero,” Sharma said.

“So in the areas where we’re really looking to prevent serious illness, prevent hospitalizations and of course prevent death, all of these vaccines are good.”

How are the COVID-19 vaccines stored?

  • Pfizer: -70°C
  • Moderna: -25°C to -15°C
  • AstraZeneca: 2°C to 8°C

Just like people, some of these vaccines are pickier than others about the temperature they like to hang around in.

Story continues below advertisement

Of the three vaccines, Pfizer is the most particular — and it likes things chilly. This vaccine requires ultra-cold storage, meaning it has to be transported and stored at -70 C. This makes the vaccine tricky to ship to remote regions, where the appropriate infrastructure is far more difficult to set up.

Click to play video 'Coronavirus: Tam says she has received no reports of COVID-19 vaccine ‘wastage’'

Coronavirus: Tam says she has received no reports of COVID-19 vaccine ‘wastage’

Coronavirus: Tam says she has received no reports of COVID-19 vaccine ‘wastage’ – Jan 5, 2021

Enter the Moderna vaccine, which is a little less discerning. While this vaccine still likes the cold, it isn’t quite as particular as the Pfizer jab. The Moderna doses can be stored in a freezer between -25 C and -15 C. That’s why the territories have been guaranteed priority access to this particular vaccine, as it’s much easier to safely transport and store.

This category is also where AstraZeneca’s vaccine truly shines. The doses can be stored at normal fridge temperature — meaning the doses are much easier to both ship and keep.

Story continues below advertisement

How many doses of each COVID-19 vaccine are required?

  • Pfizer: two
  • Moderna: two
  • AstraZeneca: two

Pfizer, Moderna and AstraZeneca’s vaccines are all two-dose shots — leaving little room for relief for those Canadians who get sweaty palms at the very thought of needles.

Some, including the head of Ontario’s vaccine rollout Gen. Rick Hillier, have pushed for Moderna to be approved as a single-dose vaccine, as the jab has proven to be about 80 per cent effective after the first injection.

However, no clinical trials have been conducted to prove whether that inoculation lasts long-term — and Moderna hasn’t shown any interest in conducting further trials to determine if less effective, one-time vaccine is a safe and effective option.

Who can take the COVID-19 vaccine?

  • Pfizer: 16+
  • Moderna: 18+
  • AstraZeneca: 18+

While Canada is on track to have tens of millions of doses available to Canadians this year, not everyone who may want the vaccine will be able to take it.

Pfizer’s clinical trials were only conducted on those over the age of 16, which means that until further studies are completed in younger age groups, anyone under 16 years old is ineligible for the jab. The same issue comes into play for both Moderna and AstraZeneca, which only conducted their clinical trials on Canadians over the age of 18.

Story continues below advertisement

Click to play video 'When will kids be able to get the COVID-19 vaccine? Experts weigh in'

When will kids be able to get the COVID-19 vaccine? Experts weigh in

When will kids be able to get the COVID-19 vaccine? Experts weigh in – Jan 26, 2021

Moderna is currently conducting additional studies in children over 12 years old, so teens may be able to access the jabs once that work is done.

However, age isn’t the only limitation those hoping to be vaccinated may face. Anyone who is allergic to the ingredients in the vaccines is not allowed to receive the injections, and pregnant or breastfeeding mothers have been asked to consult their doctors before moving ahead with their vaccinations.

Finally, if you have COVID-19, you can’t get the vaccine until you’re better.

How many doses is Canada getting?

  • Pfizer: 40 million doses
  • Moderna: 40 million doses
  • AstraZeneca: 20 million doses

Out of the three approved vaccines, individual Canadians are most likely to wind up receiving the Moderna vaccine. Canada’s agreement with Moderna is for 40 million doses — although the feds have the option of purchasing another 16 million in addition to that. The 40 million doses are enough to inoculate 20 million Canadians, over half of the population.

Story continues below advertisement

Meanwhile, Canada has 40 million Pfizer doses secured in its agreement with the manufacturer. That’s enough to inoculate another 20 million Canadians, which means that between Pfizer and Moderna alone, Canada has enough doses to vaccine every Canadian and then some.

Click to play video 'Trudeau confirms Pfizer vaccine delivery schedule, reiterates promise of COVID-19 vaccines for all Canadians ‘who want one’ by September'

Trudeau confirms Pfizer vaccine delivery schedule, reiterates promise of COVID-19 vaccines for all Canadians ‘who want one’ by September

Trudeau confirms Pfizer vaccine delivery schedule, reiterates promise of COVID-19 vaccines for all Canadians ‘who want one’ by September – Feb 12, 2021

As for the agreement with AstraZeneca, Canada has purchased 20 million doses — enough to vaccine another 10 million Canadians. That means that between the three agreements, Canada has enough doses to inoculate 40 million people, which is more than the entire population, within the year.

Should Canada opt to purchase more of any of the vaccines, there’s no guarantee they’d arrive any faster than the initial 80 million doses. Any additional doses would be entirely dependent on the manufacturer’s production capacity, which is under serious strain as every country battles to get the vaccines.

Either way, Canada’s current vaccine agreements point in an optimistic direction: every Canadian who wants a vaccine should be able to access one in 2021.

Story continues below advertisement

© 2021 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)

Source link

Continue Reading


Moderna says waiving IP rights won’t help increase vaccine supply



Moderna Inc said on Thursday that waiving intellectual property rights on COVID-19 vaccines will not help boost supply in 2021 or 2022, a day after U.S. President Joe Biden backed a proposed waiver that is aimed at giving poorer companies access.


Continue Reading


Canada allows Pfizer COVID-19 vaccine for children aged 12-15



(Corrects headline and lead to make clear that Canada was not the first nation as stated by Canadian officials, adds context from Pfizer in fourth paragraph)

By David Ljunggren

OTTAWA (Reuters) –Canada is authorizing the use of Pfizer Inc’s COVID-19 vaccine for use in children aged 12 to 15, the first doses to be allowed in the country for people that young, the federal health ministry said on Wednesday.

Supriya Sharma, a senior adviser at the Canadian federal health ministry, said the Pfizer vaccine, produced with German partner BioNTech SE, was safe and effective in the younger age group.

“We are starting to see the light at the end of the tunnel,” she told reporters.

Sharma and a health ministry spokesman said Canada was the first country to grant such an approval, but a Canadian representative for Pfizer later said Algeria permitted use of the vaccine for this age group in April. The Canadian health ministry said it had no information about the discrepancy.

The U.S. Food and Drug Administration is expected to take a similar step “very soon,” U.S. health officials said.

Separately, authorities reported the third death of a Canadian from a rare blood clot condition after receiving AstraZeneca PLC’s’s COVID-19 vaccine. The man, who was in his sixties, lived in the Atlantic province of New Brunswick.

Jennifer Russell, the chief medical officer of health in New Brunswick, said the province would continue using the AstraZeneca vaccine. Alberta reported a death from clotting on Tuesday and Quebec announced one on April 27.

“There will be rare cases where thrombosis will occur. However, the risks remain minimal compared to the risks, complications and potential consequences of COVID-19,” Russell told reporters.

Canada‘s federal government has bought tens of millions of doses of vaccines but critics complain the pace of inoculation is lagging due to bottlenecks in the 10 provinces, which are responsible for administering the doses.

Alberta will become the first province to offer COVID-19 vaccines to everyone aged 12 and over from May 10, Premier Jason Kenney said on Wednesday, a day after he introduced tighter public health measures to combat a third wave of the pandemic.

Alberta, home to Canada‘s oil patch, has the highest rate per capita of COVID-19 in the country, with nearly 24,000 active cases and 150 people in intensive care.

Around 20% of the 1,249,950 cases of COVID-19 in Canada have been reported in people under the age of 19. Canada has recorded 24,396 deaths.

(Additional reporting by Allison Martell in Toronto and Nia Williams in Calgary;Editing by Chizu Nomiyama and Sonya Hepinstall)

Continue Reading


Younger people filling up COVID-19 intensive care



By Anthony Boadle

BRASILIA (Reuters) –COVID-19 infections continue to spread fast across the Americas as a result of relaxed prevention measures and intensive care units are filling up with younger people, the director of the Pan American Health Organization (PAHO) said on Wednesday.

In Brazil, mortality rates have doubled among those younger than 39, quadrupled among those in their 40s and tripled for those in their 50s since December, Carissa Etienne said.

Hospitalization rates among those under 39 years have increased by more than 70% in Chile and in some areas of the United States more people in their 20s are now being hospitalized for COVID-19 than people in their 70s.

“Despite all we learned about this virus in a year, our control efforts are not as strict, and prevention is not as efficient,” Etienne said in a virtual briefing from Washington.

“We are seeing what happens when these measures are relaxed: COVID spreads, cases mount, our health systems become overwhelmed and people die,” she said.

Canada continues to report significant jumps in infections in highly populated provinces such as Ontario as well as in less populated territories of the North and Yukon, home to remote and indigenous communities, according to PAHO.

Puerto Rico and Cuba remain significant drivers of COVID-19 cases in the Caribbean, which is facing a new surge of the virus, PAHO directors said.

Cases are rapidly accelerating in the Guyanas and across Argentina and Colombia, where weekly case counts are five times higher today than they were this time last year and hospitals are reaching capacity in large Colombian cities.

In Central America, Guatemala is seeing significant spikes in cases and Costa Rica is reporting record-high infections.

While vaccines are being rolled out as fast as possible, they are not a short-term solution because they are in short supply, said Etienne, the World Health Organization’s regional director.

(Reporting by Anthony Boadle; Editing by Nick Macfie)

Continue Reading